ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

“During Q4, we achieved strong sequential growth across all business segments with our U.S. peripheral and coronary atherectomy franchises growing 9% and 16% over prior quarter, respectively.

Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects the survival of aerobic species and plays a prominent role in cardiovascular diseases. From the research ...

Proper placental development in early pregnancy ensures a positive outcome later on. The developmental relationship between the placenta and embryonic organs, such as the heart, is crucial for a ...

Cardiovascular disease is the leading cause of death in the United States, claiming an estimated 1 million lives, and incurring a cost of $400 billion per year. Much of cardiovascular disease can be ...

Researchers mapped 442,239 single nuclei from nonfailing human hearts to chart how cardiac cells change from fetal ...

Once the acquisition is complete, Cardiovascular Systems' devices will join Abbott’s own range of vascular-disease-focused products. That’ll include the company's existing guidewires, catheters and ...

The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated ...

“We are pleased with the state of our business and our performance in the first quarter. Q1 revenue of $59.7 million represented 2.2% revenue growth compared to last year. Worldwide coronary revenue ...